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1. Introduction 
Designing drugs to selectively target specific protein-RNA 
interactions remains extremely challenging1 due to the large and 
flexible interacting surfaces, the complex structural plasticity, 
and the negatively charged and solvent exposed surfaces of RNA. 
Nevertheless, for human immunodeficiency virus (HIV) and 
other retroviruses with small genomes (and thus few proteins for 
targeting by drugs), viral RNA and RNA-binding proteins are 
important targets for therapeutic intervention. Common to a 
number of RNA-binding proteins is their role as transporters.2 
For example, HIV-1 Rev is a 116 residue viral protein that plays 
a critical role in HIV replication3,4 by binding to RNA (Figure 1) 
in the nucleus of a virus-infected host cell and transporting it to 
the cytoplasm for translation into viral structural and functional 
proteins that assemble into new viral particles.3 Specific 
inhibitors of the binding of the HIV-1 Rev protein to its RNA 
partner might inhibit HIV replication, however very few 
compounds are known to potently antagonize this interaction.4-8 
Among known inhibitors are peptides,4,5 aminoglycoside 
antibiotics (e.g. neomycin B),6 nucleic acid aptamers,7 and other 
small molecules.8 All of these ligands have issues with either 
bioavailability, stability, selectivity or potency in vivo. Here we 
focus on promoting alpha helicity and enhancing affinity of the 
RNA-binding HIV-1 Rev peptide sequence by incorporating 
highly alpha helical cyclic pentapeptides9 at the N-terminus and 
within the arginine-rich RNA-binding component of Rev. The 
effects of introducing these cyclic peptides on helix induction 
and affinity for the Rev-binding element RRE of RNA is 
reported.  
 
Figure 1. RNA-bound Rev34-50 peptide (PDB:1ETF).10 (a) HIV-1 
Rev residues 34-50 (red; peptide 1) bound to its double stranded 
RNA target sequence (green/yellow; Rev Response Element, 
RRE). (b) End view of the NMR-derived solution structure of H-
Rev34-50-OH peptide bound to the RRE. Residue numbers 
correspond to the Rev protein.  
 
The Rev protein (18kDa) has two distinct functional domains 
identified through mutagenesis.11 The N-terminal domain 
contains both the nuclear localisation signal and the RNA-
binding domain (RBD), whereas the C-terminal domain contains 
the nuclear export signal. A 17-residue arginine-rich region in the 
N-terminal domain of Rev, residues 34-50, is important for both 
targeting to the nucleus12 and specific binding to the major 
groove of the RNA segment termed the Rev Response Element 
(RRE).4 When isolated, this short synthetic peptide sequence 
corresponding to HIV-1 Rev34-50 (H-
TRQARRNRRRRWRERQR-NH2; denoted from this point on as 
peptide Rev1-17 or peptide 1) has negligible structure in water but 
becomes alpha helical when 2,2,2-trifluoroethanol (TFE) is 
added,13 or when bound to the Rev Response Element4,10 (Figure 
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HIV-1 Rev is a 116 residue transporter protein that enters the host cell nucleus and uses its
17 amino acid segment (Rev34-50) to bind and capture a specific piece of RNA, the Rev 
Response Element (RRE), for transport to the cytoplasm. This is critical for HIV 
replication. In isolation, Rev34-50 shows negligible structure in water, but is alpha helical in 
a mixture of water and 2,2,2-trifluoroethanol (TFE) or when bound to RRE. Here we report
that helix-constrained cyclic pentapeptides, either appended to the N-terminus or
incorporated within Rev34-50, are efficient helix nucleators in water. They induce up to 90% 
alpha helicity for isolated Rev peptides in water and confer high RNA-binding affinity.  
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1). Alanine mutagenesis of this 17-residue peptide4a revealed 
that Thr1, Arg2, Arg5, Arg6, Asn7 and Arg11 were critical for 
high affinity binding to RRE and for specificity over other RNA 
segments, while Arg13, Arg15 and Arg17 also made important 
electrostatic interactions.  
2. Results and discussion 
    Previously, we reported on a cyclic pentapeptide, Ac-(1,5-
cyclo)-[KARAD]-NH2, that formed a single α-helical turn with 
unusually high stability in water.9a This pentapeptide contained a 
crucial lactam bridge between the side chains of lysine (position 
1) and aspartic acid (position 5), which promoted formation of 
three α-helix-defining hydrogen bonds within the peptapeptide.9a 
This lactam bridge was more effective in inducing alpha helicity 
within pentapeptides than any other lactam bridge9a or other 
hydrocarbon linkers between side chains of residues 1 and 5.14a 
Moreover, helicity was tolerant of many amino acids at positions 
2, 3 and 4 in the sequence,14a,b helix-favouring amino acids in 
these positions in proteins also favoured helicity in the cyclic 
pentapeptide,14b and the cyclic pentapeptides could be combined 
as modules9b to confer alpha helicity in, and biological activity to, 
longer peptide sequences.14b-f We therefore decided to examine 
its influence here on alpha helicity when appended to the end, or 
within, the Rev peptide sequence corresponding to the RNA-
binding domain.  
Using the NMR solution structure of Rev1-17 (1) bound to RRE 
(pdb:1ETF),10 we first modelled whether the cyclic pentapeptide 
attached to the N- or C-terminus might sterically clash with the 
RNA. There was insufficient space to permit attachment of the 
cyclic peptide to the C-terminus of 1 and, even when attached to 
the N-terminus of 1, there were clashes with the RNA backbone 
bases of G47-G48 (Figure 2) that would be expected to 
negatively impact on binding affinity. To avert this potential 
problem, a series of models were created for Ac-(1,5-cyclo)-
[KARAD]-Ala(n)-Rev1-17-NH2, with different numbers of alanine 
residues (n = 0-4) as spacers with high helical propensity and 
small side chains to limit steric interference with the RNA 
backbone. We found that at least three alanine residues were 
needed to separate the Rev peptide from the cyclic peptide and 
thereby minimise steric clashes between the cycle and the RNA 
(Figure 2). The models suggested that the side chain lactam 
bridge may interact with the RRE backbone 64-GCU-66 when n 
= 2, but that n ≥ 3 would enable the side chain lactam bridge to 
be projected beyond the RNA backbone and thus would not be 
expected to interfere with binding (Figure 2). We therefore 
synthesized H-Rev1-17-NH2 (1), Ac-(1,5-cyclo)-[KARAD]-Rev1-
17-NH2 (2), and Ac-(1,5-cyclo)-[KARAD]-Ala-Ala-Ala-Rev1-17-
NH2 (3) to test for steric interference and for experimental 
comparison of helix induction and RNA binding affinities. 
 
Figure 2. Models of N-terminally capped Rev peptides bound to 
the RRE. (a) compound 2; (b)  compound 3. Rev34-50 is shown in 
green, Ac-(1,5-cyclo-[KARAD])- is in pink, and the -Ala-Ala-
Ala- linker is in black. 
Circular dichroism spectra (Figure 3a) showed that the Ac-
(1,5-cyclo)-[KARAD]-
 
unit was a very effective N-terminal helix 
nucleator, improving alpha helicity from 6% (compound 1) to 
54% (compounds 2 and 3) in aqueous 10 mM phosphate buffer 
(pH 7.0, 22°C). Interestingly, helical induction by the N-terminal 
helix-constrained
 
cyclic pentapeptide
 
was the same with 
(compound 3) or without (compound 2) the Ala-Ala-Ala spacer 
between cyclic peptide and Rev peptide (Figure 3a). This 
induction of α-helicity using the N-terminal helix-constrained 
cyclic peptide also improved the binding affinity for RRE 
(Figure 3b) from IC50 886 nM (1) to IC50 260 nM (2). A further 
increase to IC50 91 nM for 3, despite comparable α-helicity to 2, 
was attributed to more favourable fitting of 3 into RRE without 
the steric clash predicted earlier for 2 (Figure 2a).  
Figure 3. (a) Circular dichroism spectra of uncapped H-Rev1-17-
NH2 peptide (1, black) versus N-terminally capped peptides Ac-
(1,5-cyclo)-[KARAD]-Rev1-17-NH2 (2, blue) and Ac-(1,5-cyclo)-
[KARAD]-Ala-Ala-Ala-Rev1-17-NH2 (3, red), measured in 10mM 
phosphate buffer (pH 7.0) at 22°C. (b) Competitive binding of N-
terminal capped Rev peptides 1 (black), 2 (blue), 3 (red) for RRE 
using 10nM Suc-Rev1-17-AAAAC(fluorescein)-NH2 (Kd = 7 nM) 
and 7.5nM biotin-labelled RRE. 
  
Figure 4. Structure of peptide 3 in water (N-terminal cycle on 
left). (a) Summary of sequential, short and medium range NOE 
data in 90% H2O:10% D2O at 298K. NOE intensities were strong 
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(upper distance constraint 2.7Å), medium (3.5Å), weak (5.0Å), 
very weak (6.0Å) and proportional to bar thickness. 3JNHCHα < 
6Hz indicated by ↓. (b) 20 lowest energy structures with 
K(i)→D(i+4) lactam bridge in grey and backbone conformation 
in pink ribbon. Residues of the cyclic peptide, three spacer 
alanines, and Rev1-11 are in the helix, while Rev12-17 are 
disordered. (c) NMR structure of 3 modelled to bind in RRE. 
Residues important for binding and specificity are in orange 
(Thr1, Arg2, Arg5, Arg6, Asn7, Arg11, Arg13). 
     Using 2D 1H-NMR spectroscopy, we determined a solution 
structure for 3 in water (Figure 4) that showed the N-terminal 
cyclic peptide plus the linker plus Rev1-11 in an alpha helical 
conformation, while Rev12-17 was disordered. This is consistent 
with CD spectra above where only 54% helix induction was 
found for 3 in water, NMR structures for 3 in 90% H2O:10% D2O 
at 298K (mixing time 200 ms) were calculated from 69 NOE-
derived distance (short, medium, long range) and 21 3JNHHα-
dihedral angle restraints derived from NOESY spectra. Small 
3JNHHα coupling constants and several dNN(i,i+1), dαN(i,i+3) and 
dαN(i,i+4) NOEs were indicative of alpha helical structure for 3 in 
water (Figure 4a). The 20 lowest energy calculated structures 
(Figure 4b) showed no φ-dihedral angle (>5°) or distance (>0.2 
Å) violations and relatively well-defined α-helical turns, frayed 
at the C-terminus with overall RMSD (residues 2 to 20) = 1.95 Å 
(Pymol software). The NMR-derived structure for 3 resembled 
Rev34-50 bound to RNA, with most of the important residues in 3 
(Thr1, Arg2, Arg5, Arg6, Asn7, Arg11, Arg13; orange in Figure 
4c) being in the alpha helix of 3 and corresponding to those in 
Rev34-50 that contact RNA. 
Figure 5. Helical wheel diagrams illustrating key residues at 
positions i and i+4 in the 17-residue sequence on the same face of 
an alpha helix. This was used along with Ala mutagenesis data4a 
to position K(i)→D(i+4) lactam bridges to constrain Rev 
peptides 4-8 into α-helices. Linkers in red. Residues in blue are 
important for binding and specificity for RRE.  
An alternative to placing the helix-inducing cyclic 
pentapeptide constraint at the end of the Rev1-17 sequence is to 
incorporate it within the sequence. Because of the large interface 
between Rev1-17 and RRE (988Å2 determined using the PISA 
server),15 we were concerned that lactam bridges inserted into the 
Rev peptide might sterically impede binding to RRE. Modelling 
predictions suggested that this might be the case, but we 
proceeded anyway hopeful that peptide-RNA cooperativity might 
enable cyclic mimics to fit allowable space.  Taking care to avoid 
replacing the important binding residues (Thr1, Arg2, Arg5, 
Arg6, Asn7 Arg11, Arg13, Arg15, Arg17), we designed (i, i+4) 
lactam bridges across positions 4-8, 5-9, 8-12, 10-14 and 12-16 
(Figure 5). This led to five peptides (4-8) incorporating two 
differently spaced helix-constraining cyclic pentapeptide 
modules: Ac-(5,9; 10,14-cyclo)-TRQA[KRNRD][KRWRD]-
NH2 (4), Ac-(5,9; 12,16-cyclo)-TRQA[KRNRD]RR[KRERD]-
NH2 (5), Ac-(4,8; 10,14-cyclo)-TRQ[KRRND]R[KRWRD]-NH2 
(6), Ac-(5,9; 8,12-cyclo)-TRQA[KRN[KD]RRD]RERQ-NH2 (7) 
and Ac-(4,8; 12,16-cyclo)-TRQ[KRRND]RRR[KRERD]-NH2 
(8). These all feature two cyclic pentapeptide modules, either 
back-to-back with no spacer (4) or spaced by one residue (6), two 
residues (5), three residues (8), or overlapping one another (7).  
Circular dichroism spectra (Figure 6a) demonstrated that the 
cyclic pentapeptide dramatically increased α-helicity in all five 
compounds 4-8 (55-92%, Table 1) relative to 1 (6%), indicating 
effective induction of alpha helicity across and beyond the 
cyclised regions. The two most alpha helical peptides (5, 6) had 
the highest competitive binding affinities for RRE (Table 1, 
Figure 6b), with IC50 223 nM (5) and 440 nM (6). However, 
compounds 5 and 6 were not as potent as the N-terminal capped 
analogue 3. 
Figure 6. (a) Circular dichroism spectra of Rev34-50 peptide (1) 
and derivatives incorporating one or two -(1,5-cyclo)-[KXXXD]- 
motifs at various positions (4-8) measured in 10mM phosphate 
buffer (pH 7.0) at 22°C. Compounds 1 (black), 4 (magenta), 5 
(green), 6 (purple), 7 (brown), 8 (orange). (b) Binding isotherms 
for interaction with RRE-biotin. Competitive binding of peptides 
1 (black), 5 (green), 6 (purple) for RRE using 10nM Suc-Rev1-17-
AAAAC(fluorescein)-NH2 (Kd = 7 nM) and 7.5nM biotin-
labelled RRE. 
Compound 4, Ac-(5,9-10,14-cyclo)-TRQA[KRNRD] 
[KRWRD]-NH2 had appreciable helicity (fH = 0.64) but showed 
low binding affinity for RRE (IC50 10 µM).  Molecular modelling 
had suggested that the K(5) → D(9) and K(10) → D(14) lactam 
bridges in 4 are on two different faces of an α-helix (Figure 5) 
and potentially hinder interactions with RNA. To test this notion, 
we had synthesised compound 5, Ac-(5,9-12,16-cyclo)-
TRQA[KRNRD]RR[KRERD]-NH2, where we altered the 
location of the second lactam bridge by placing two amino acids 
between the lactam bridges. This synchronizes the lactam bridges 
onto the same α-helical face in 5, making them less likely to 
interfere with binding to RNA. This was evident from the 200-
fold improvement in RRE-binding affinity for 5 (IC50 223 nM) 
relative to 4 (IC50 10 µM). Compound 6 with one residue 
between the cycles (IC50 440 nM) was somewhat tolerated, but 
three alanines inserted between the cycles in compound 8 (IC50 
1660 nM) were not well tolerated. These observations were in 
agreement with modelling of these cyclic-constrained helices into 
the RNA, which revealed some steric clashes. Compound 7, 
which overlaps with the cyclic regions, reduces the number of 
RNA-interacting residues and accordingly reduced affinity for 
RRE (IC50 1820 nM).  
The lower affinity for RRE of the 16-residue peptide 5 (IC50 
223 nM), containing two cyclic peptide constraints, over the 25-
residue peptide 3 (IC50 91 nM, Table 1) cannot be explained by 
differences in steric hindrance of lactam bridged side chains.  
Rather this difference is attributed to the required replacement of 
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a key amino acid to cater for the lysine residue of the lactam 
bridge.  In Ac-(5,9-12,16-cyclo)-TRQA[KRNRD]RR[KRERD]-
NH2 (compound 5), Arg5 had to be replaced with Lys5 in order 
to synthesise the lactam bridge. An earlier alanine-scan study of 
Rev1-17 had shown that Arg5 has a specific role in binding to 
RRE and that the Arg5Ala mutant reduced specific binding 10-
fold from the wild-type Rev1-17 peptide.4a  Furthermore, the NMR 
structure of the Rev1-17:RRE complex suggests that Arg5 makes 
bridging hydrogen bonds between U66 and G67 of the RRE.10 
This data is supported by earlier work showing that Arg5 cannot 
be functionally replaced by lysine.4c It therefore seems likely that 
replacement of Arg5 explains the reduction in binding affinity.  
Table 1. Summary of competitive binding affinities and molar 
ellipticities for compounds 1-8 (10 mM PBS, pH 7.2, 298K).  
Compound* fH -log IC50 ± SEM IC50 (nM) ∆∆G 
1 0.06 6.05 ± 0.05 886 -- 
2 0.54      6.59 ± 0.05 260 3.01 
3 0.54 7.04 ± 0.06 91 -5.55 
4 0.64 4.98 ± 0.07 10 000 5.94 
5 0.92 6.65 ± 0.04 223 -3.83 
6 0.87 6.36 ± 0.05 440 -1.72 
7 0.79 5.74 ± 0.32 1 820 1.77 
8 0.55 5.78 ± 0.07 1 660 1.54 
*Maximum 10 µM tested. ∆∆G = -RTln[IC50(1)/IC50(2)] was determined in 
kJ.mol-1K-1 relative to compound 1. 
       To confirm the extent and location of α-helicity in the 
cyclic-constrained peptide 5, we determined its NMR-derived 
solution structure in water (Figure 7), calculated using a dynamic 
simulated annealing and energy minimisation protocol in X-
PLOR, using 106 NOE-derived distance restraints (23 sequential, 
67 medium-long range), 15 backbone φ-dihedral constraints and 
10 hydrogen bonds. The structure of 5 confirmed its helical 
nature in water, as identified in the CD spectra, with ∆δ αH 
chemical shifts all greater than -0.10 ppm and almost all residues 
in the cyclised region (residues 5-16) having ∆δ αH values 
greater than -0.20 ppm, except for D9 and D16.  We had 
previously seen this trend for aspartic acid residues in Ac-1,5-
cyclo-[KXXXD]-NH2 with decreased ∆δ αH.9,14  Furthermore, 
variable temperature data suggested that amide protons of Ala4, 
Lys6, Arg6, Arg8, Arg11, Lys12, Arg13, Arg15, Asp16 and the 
C-terminal amide were all involved in hydrogen bonds (Figure 
7). Finally, the 3JNHCHα coupling constants, with the exception of 
those for Asp16 and the terminal amide, were all less than 6 Hz. 
In combination, this data supports that all sixteen residues in 
compound 5 are in a helical conformation. 2D NOESY spectra 
were collected for compound 5 with sequential NOEs dominant, 
as well as significant medium-long range NOEs (dαN(i,i+3), 
dαβ(i,i+3)).  Additional weaker NOEs (dNN(i,i+2), dαN(i, i+2)), and 
especially dαN(i, i+4) were also observed throughout the peptide 
sequence, supporting the existence of a continuous α-helix 
(Figure 7). 
    The 20 lowest energy calculated structures (Figure 8) did not 
have any φ-dihedral angle (>5°) or distance (>0.3Å) violations 
and showed relatively well-defined α-helical turns with overall 
RMSD (residues 2 to 15) = 0.470 Å (Pymol software, 54 of 56 
atoms used in calculation). The constraints are thus able to 
transfer α-helicity to those residues 1-4 and 10-11 outside of the 
cyclic regions. Compound 5 also closely aligns with the RRE-
bound conformation of the Rev peptide, with its superposition on 
the lowest energy conformation of the RRE:Rev NMR structure 
(pdb: 1ETF) showing an overall RMSD = 0.755 Å (using 
residues 35-48 of pdb:1ETF and residues 2-15 of compound 5). 
 
Figure 7. Summary of sequential, short and medium range NOE 
data for 5 in 90% H2O 10% D2O at 298K. NOE intensities were 
classified as strong (upper distance constraint 2.7Å), medium 
(3.5Å), weak (5.0Å), very weak (6.0Å) and are proportional to 
bar thickness; grey bars indicate overlapping signals and empty 
bar for NOE not observed due to proximity to diagonal. 3JNHCHα < 
6Hz are indicated by ↓ and ∗ for broad signals. Temperature 
insensitive amide NHs for which chemical shifts changed by < 
4ppb/K are indicated by •. 
  
Figure 8. Lowest energy calculated structures for 5.  (a) Lowest 
energy structure showing proposed hydrogen bonds. (b) 20 
lowest energy structures showing position of the K(i) → D(i+4) 
lactam bridges (grey). (c) Superimposition of compound 5 (red) 
on H-Rev1-17-OH (black) bound to RRE (pdb 1ETF) showing the 
Cα-Cβ bonds of Thr1, Arg6, Asn7 and Arg11 as spheres. 
In terms of free energy, the data in Table 1 suggest that at 
least 6 kJ.mol-1.K-1 can be gained by constraining the peptide into 
an α-helical conformation (this may be a maximum value), 
provided that the helix-inducing constraint is appropriately 
positioned.  In this particular interaction, the RNA may also 
assist peptide folding through electrostatic interactions between 
the negatively charged phosphate backbone and positively 
charged arginine side chains.  
3. Conclusion 
 In summary, we have used Rev-RNA structures to select 
appropriate locations for incorporating helix-constrained cyclic 
peptides into the RNA-binding domain of HIV-1 Rev peptide, the 
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17-residue sequence TRQARRNRRRRWRERQR-NH2. This 
peptide alone was not helical in water but has helical propensity, 
since it becomes helical when bound to the RNA segment known 
as RRE. We have demonstrated that helix-constrained cyclic 
pentapeptides are able to nucleate extensive alpha helicity in Rev 
peptides, even in the highly polar solvent water which competes 
very effectively for hydrogen bonding partners. When appended 
to the N-terminus of the isolated Rev peptide sequence, a cyclic 
pentapeptide was most effective in promoting binding to the RRE 
target when it was spaced three or more residues from the N-
terminus. This spacing minimises steric clashes between the 
appended cyclic peptide helix and the RNA bases. Alternatively, 
the helix-constrained cyclic pentapeptides can be incorporated as 
modular helical templates within the Rev peptide sequence, also 
conferring increased alpha helicity and higher affinity binding to 
the RRE. Calculations suggest that this helix pre-organization in 
water confers an advantage of 2 to 6 kJ.mol-1.K-1 to the Rev 
peptide for binding to RNA. 
4. Experimental section 
Synthesis of peptides 1-8. Peptides were synthesized 
manually by standard solid phase methods using HBTU/DIPEA 
activation of Fmoc on Rink Amide resins (substitution 0.30-0.50 
mmol/g, 0.2-0.5 mmol scale, 0.50-1.00 g resin). Four equivalents 
of Fmoc-protected amino acid, 4 equivalents of HBTU, and 4 
equivalents of DIPEA were used in each coupling. Fmoc 
deprotection involved 2 × 3 min treatments with excess 1:1 
piperidine:DMF. Coupling yields were monitored by quantitative 
ninhydrin assay. The phenylisopropyl ester of aspartic acid and 
methyltrityl group of lysine were removed by treating the peptide 
resin with 3% TFA in DCM (5 × 2 min). The resin was 
neutralised by washing with 5% DIPEA in DMF (2 x 3min). 
Cyclization was effected on-resin using BOP, DIPEA in DMF.  
The peptide resin was then washed with DMF, MeOH/DCM and 
DCM, dried under nitrogen with suction for 20 min. Peptides 
were cleaved using 95% TFA, 2.5% TIPS, 2.5% H2O. Peptides 
were precipitated with diethyl ether and then decanted to give 
white solids that were re-dissolved in 1:1 acetonitrile/water and 
lyophilised. The crude peptides were purified by rp-HPLC 
(Rt:Vydac C18 column, 300 Å. 22 × 250mm, 214nm, Solvent A 
= 0.1% TFA in H2O, Solvent B = 0.1% TFA, 10% H2O in 
acetonitrile. Gradient: 0% B to 100% B over 30 mins).  
H-TRQARRNRRRRWRERQR-NH2 (1):. Rt: 14.25 min. MS 
[M+H]+ = 2437.69 (found), 2436.41 (calc.). Ac-(1,5-cyclo)-
[KARAD]TRQARRNRRRRWRERQR-NH2 (2): Rt: 13.8 min. 
MS [M+6H]6+ = 501.09 (found), 501.12 (calc.). Ac-(1,5-cyclo)-
[KARAD]AAATRQARRNRRRRWRERQR-NH2 (3): Rt: 15.5 
min. MS [M+6H]6+ = 536.58 (found), 536.64 (calc.). Ac-(5,9; 
10,14-cyclo)-TRQA[KRNRD][KRWRD]-NH2 (4): Rt: 17.2 min. 
MS [M+2H]2+ = 946.00 (found), 946.02 (calc.). Ac-(5,9; 12,16-
cyclo)-TRQA[KRNRD]RR[KRERD]-NH2 (5) Rt: 13.3 min. MS 
[M+2H]2+ = 1102.51 (found), 1102.61 (calc.). Ac-(4,8; 10,14-
cyclo)-TRQ[KRRND]R[KRWRD]-NH2 (6) Rt: 13.6 min. MS 
[M+2H]2+ = 988.50 (found), 988.55 (calc.) . Ac-(5,9; 8,12-
cyclo)-TRQA[KRN[KD]RRD]RERQ-NH2 (7) Rt: 14.2 min. MS 
[M+3H]3+ = 707.03 (found), 706.73 (calc.). Ac-(4,8; 12,16-
cyclo)-TRQ[KRRND]RRR[KRERD]-NH2 (8) Rt: 14.4 min. MS 
[M+3H]3+ = 744.40 (found), 744.43 (calc.) 
Circular Dichroism Spectroscopy. CD experiments were 
performed on a Jasco model J-810 spectropolarimeter calibrated 
with (1S)-(+)-10-camphorsulfonic acid. Spectra were recorded in 
a 0.1cm Jasco cell between 260-185 nm at 50 nm/min with a 
bandwidth of 1.0 nm, response time of 2 s, resolution step width 
0.1 nm and sensitivity 20, 50 or 100 mdeg. Each spectrum is the 
average of 5 scans with smoothing to reduce noise. Peptide 
samples were dissolved in 1 mL of 18MΩ distilled water (~1-4 
mg/mL). Each stock solution (400 µL) was then diluted 1:10 with 
phosphate buffer (10 mM, pH 7.2), while the remaining 600 µL 
was kept for concentration determination. Solutions were then 
prepared for each sample with final concentrations 40 – 400 µM 
in 10 mM sodium phosphate buffer (pH 7.2).  
Concentrations were determined using the PULCON method.16  
Pulses (90o) were accurately determined, then 1D spectra were 
acquired using standard Watergate sequence with ns = 32-64, rg 
= 128-512, d1 = 30 sec. Several fully resolved signals were 
integrated and used to calculate concentration from the equation: 
 
where c is concentration, S is integral (in absolute units/number 
of protons), T is temperature in Kelvin, θ360º is 360o rf pulse, n is 
the number of scans, and rg is receiver gain used for measuring 
the reference (R) and unknown (U) samples.  
CD ellipticity (in millidegrees) was converted to residue 
molar ellipticity (deg.cm2.dmol-1.residue-1) using [θ] = θraw /(10 × 
C × N × l), where θraw is ellipticity in millidegrees, C is peptide 
concentration (mol/L), l is optical path length of cell (cm), and N 
is number of peptide units.  
Percent Helicity of peptides was calculated from residue-
molar elipticity at λ = 222 using eq:  fhelix = ([θ]222 - [θ]0)/( [θ]max - 
[θ]0). [θ]max ([θ]max = [θ]∞(n – x)/n) is the maximum theoretical 
mean residue ellipticity for a helix of n residues, [θ]∞ is the mean 
residue ellipticity of an infinite helix, and x is an empirical 
constant that can be interpreted as the effective number of amides 
missing as a result of end effects, usually about 2.4-4 (we used 
x=3) and [θ]∞ = (-44000 + 250T) (T is temperature of the peptide 
solution in ˚C). [θ]0 is the mean residue ellipticity of the peptide 
in random coil conformation and equals to (2220 – 53T) and 
[θ]222 ([θ]222 = 1/n . [θobs]/(10 x l x C)) is the observed residue 
ellipticity of peptide at 222 nm. θobs = measured ellipticity in 
mdeg; n = number of peptide residues; C = sample concentration 
(mol/L); l = optical path length of the cell in cm. 
NMR Spectroscopy. Peptides (1-2 mg) were dissolved in 
600 µL of H2O:D2O (9:1) or H2O:CD3CN (1:1) at pH 5.0. 1D and 
2D 1H-NMR spectra were recorded on a Bruker Avance DRX-
600 spectrometer. 2D 1H-spectra were recorded in phase-
sensitive mode using time-proportional phase incrementation for 
quadrature detection in the t1 dimension.  The 2D experiments 
included TOCSY (standard Bruker mlevgpph pulse program), 
ROESY (standard Bruker roesygpph pulse program), NOESY 
and dqfCOSY (standard Bruker dqfcosygpph pulse program). 
TOCSY spectra were acquired over 6887 Hz with 4096 complex 
data points in F2, 512 increments in F1 and 32 scans per 
increment. NOESY spectra were acquired over 6887 Hz with 
4096 complex data points in F2, 512 increments in F1 and 32 
scans per increment. TOCSY and NOESY spectra were acquired 
with several isotropic mixing times of 80, 100 ms for TOCSY 
and 200-300 ms for NOESY. Water suppression was achieved 
using modified WATERGATE. For 1D 1H NMR spectra 
acquired in H2O/D2O (9:1), the water resonance was suppressed 
by low power irradiation during the relaxation delay (1.5 to 3.0 
s). The variable NMR experiments were performed over the 
range of 278-318K. Spectra were processed using Topspin 
(Bruker, Germany) software and NOE intensities were collected 
manually. The t1 dimensions of all 2D spectra were zero-filled to 
1024 real data points with 90˚ phase-shifted QSINE bell window 
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functions applied in both dimensions followed by Fourier 
transformation and fifth order polynomial baseline correction. 1H 
chemical shifts were referenced to DSS (δ 0.00 ppm) in water. 
3JNHCHα coupling constants were measured from 1D 1H NMR and 
dqf-COSY spectra using XPLOR program.  
Structure Calculations. Distance restraints used in 
calculating the structure for 5 in water were derived from 
NOESY spectra (recorded at 298K) using a mixing time of 200 
ms. NOE cross-peak volumes were classified manually as strong 
(upper distance constraint ≤ 2.7Å), medium (≤ 3.5Å), weak (≤ 
5.0Å) and very weak (≤ 6.0Å). Standard pseudoatom distance 
corrections were applied for non-stereospecifically assigned 
protons. To address the possibility of conformational averaging, 
intensities were classified conservatively and only upper distance 
limits were included in the calculations to allow the largest 
possible number of conformers to fit the experimental data. 
Backbone dihedral angle restraints were inferred from amide 
3JNHCHα coupling constants in 1D spectra, φ was restrained to –65 
± 30° for 3JNHCHα ≤6Hz and to -120 ± 30° for 3JNHCHα ≥ 8Hz.  
There was clearly no evidence for cis-amides about peptide 
bonds (i.e. no CHα-CHα (i, i+1) NOEs) in the NOESY spectra 
so all ψ-angles were set to trans (ψ = 180˚). Starting structures 
with randomised φ and ψ angles and extended side chains were 
generated using an ab initio simulated annealing protocol. The 
calculations were performed using the standard forcefield 
parameter set (PARALLHDG5.2.PRO) and topology file 
(TOPALLHDG5.2.PRO) in XPLOR-NIH with in house 
modifications to generated lactam bridges between lysine and 
aspartic acid residues. Refinement of structures was achieved 
using the conjugate gradient Powell algorithm with 4000 cycles 
of energy minimisation and a refined forcefield based on the 
program CHARMm.17 Structures were visualised with Pymol and 
analysed for distance (>0.2Å) and dihedral angle (>5o) violations 
using noe.inp (in Xplor) files. Final structures contained no 
distance violations (>0.2Å) or angle violations (>5o). 
Molecular modelling. Three-dimensional models of 2 and 3 
were built by using Insight II18 to covalently link the NMR 
structure of Ac-(1,5-cyclo)-[KARAD]-NH2 9b to the linear Rev 
peptide (idealised alpha helix) with and without spacer 
sequences. All images of peptides incorporating cyclic 
constraints were visualised using MacPymol19 or Oemga2 
(OpenEye Scientific Software). 20  
RRE-Rev Affinity and Competitive Binding. Kd was 
determined by adapting a reported assay,21 using 10nM 
fluorescein-labelled Rev (succinyl-TRQARRNRRRRWRER-
QRAAAARC-fluorescein) and increasing concentrations of 
RRE-biotin 5’-GGU AUG GGC GCA GCG CAA GCU GAC 
GGU ACA GGC C-3’-biotin (Ambion, USA) in assay buffer 
(30mM HEPES pH 7.5, 100 mM KCl, 40 mM NaCl, 10 mM 
ammonium acetate, 10 mM guanidinium HCl, 2 mM MgCl2, 0.5 
mM EDTA, 50 µg/ml E.coli tRNA (Sigma) and 0.01% Igepal). 
10µg AlphaScreen FITC Acceptor beads (Perkin Elmer) were 
added and the plate was incubated for 30 minutes. 10 µg 
AlphaScreen FITC Donor beads (Perkin Elmer) were added to 
each well and the plate was incubated for a further 30 minutes 
and read using the Envision (Perkin Elmer). For competition 
assays, 10 nM suc-TRQARRNRRRRWRERQRAAAARC-
fluorescein and 7.5 nM RRE-biotin were incubated with 
increasing concentrations of unlabelled peptides.  Data was fitted 
using equation: Y= [bottom + (top – bottom)]/[1 + 10(logEC50 – 
X)*hillslope], where EC50 can also be IC50, depending on experiment. 
Free energy calculations (∆∆G binding). Delta delta values 
of binding were calculated using the standard formulae ∆G = -
RTlnKeq and ∆∆G = -RTln[Keq(1)/Keq(2)]. Although we do not 
have Keq values for all our compounds, we were able to use the 
IC50 values obtained from the competitive binding data.  We can 
use the assumption that the ratio of Keq(1) / Keq(2) ≈ IC50 (1) / IC50 (2) 
as illustrated in the literature.22 The IC50 values are comparable to 
each other as they were obtained under the same experimental 
conditions. We and others23 have used the IC50 values to calculate 
differences in the free energy of binding by combining equation 
to ∆∆G = -RTln[IC50(1)/IC50(2)]. 
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